EAM
BLTE

Eventide Asset Management’s Belite Bio BLTE Stock Holding History

Eventide Asset Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57M Sell
357,650
-25,441
-7% -$4.28M 0.94% 31
2025
Q4 		$61.3M Buy
383,091
+187,779
+96% +$22.2M 0.96% 27
2025
Q3 		$14.5M Buy
+195,312
New +$12.8M 0.24% 114

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Eventide Asset Management's BLTE Position: Q1 2026 in Review

Eventide Asset Management reduced its Belite Bio (BLTE) stake by 6.6% in Q1 2026, selling an estimated $4.28M and leaving 357,650 shares worth $57M. The position accounts for 0.94% of the portfolio, ranked #31.

Eventide Asset Management first reported a position in BLTE in Q3 2025 and has held it in 3 quarters since. The position peaked at $61.3M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Eventide Asset Management held 357,650 shares of Belite Bio worth $57M as of Q1 2026.
  • Eventide Asset Management sold 25,441 Belite Bio shares in Q1 2026, an estimated $4.28M.
  • Belite Bio made up 0.94% of Eventide Asset Management's portfolio in Q1 2026, its #31 holding.
  • Eventide Asset Management first reported a position in Belite Bio in Q3 2025 and has held it in 3 quarters since.
  • Eventide Asset Management's Belite Bio position peaked at $61.3M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.